DEFINING DYNORPHIN-CRF CIRCUITS IN STRESS AND NICOTINE BEHAVIORS

定义压力和尼古丁行为中的强啡肽-CRF 回路

• 批准号: 9021634
• 负责人: Ream Al-Hasani
• 金额: $ 14.01万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-03-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9021634
• 关键词: Adverse effects; Affective; Amygdaloid structure; Anxiety; Anxiety Disorders; Attention; Award; Behavior; Behavior Control; Behavioral Paradigm; Brain region; CRF receptor type 1; Cell Nucleus; Cells; Cessation of life; Characteristics; Chronic; Chronic stress; Corticotropin-Releasing Hormone; Data; Development; Drug Addiction; Drug abuse; Dynorphins; Exposure to; Goals; Health; Incidence; Intake; Internal Ribosome Entry Site; Knockout Mice; Lead; Learning; Link; Measures; Mediating; Mediation; Mediator of activation protein; Mental Depression; Mentors; Microdialysis; Modeling; Mus; Negative Reinforcements; Neurons; Neuropeptides; Neurosciences; Nicotine; Nicotine Dependence; Nicotine Withdrawal; Nucleus Accumbens; Opioid; Opioid Receptor; Pathway interactions; Pharmaceutical Preparations; Pharmacology; Phase; Population; Process; Property; Receptor Activation; Regulation; Relapse; Research; Role; Serotonergic System; Signal Transduction; Site; Source; Stress; Substance Withdrawal Syndrome; System; Technical Expertise; Technology; Testing; Therapeutic; Tobacco use; Training; Wireless Technology; Withdrawal; Work; acute stress; anxiety-like behavior; behavioral pharmacology; behavioral response; biological adaptation to stress; cell type; cigarette smoking; driving behavior; drug abuse vulnerability; drug withdrawal; dysphoria; in vivo; insight; liquid chromatography mass spectrometry; multidisciplinary; negative emotional state; neural circuit; neurochemistry; novel; optical fiber; optogenetics; small molecule; smoking cessation; success; transmission process

DESCRIPTION (provided by applicant): The overall goal of this research is to better understand role of dynorphin and CRF in negative affective behaviors that are associated with nicotine withdrawal. Both dynorphin and CRF systems have been shown to drive stress and aversive behaviors but few studies have determined how these systems modulate one another to drive these behaviors through the extended amygdala. Dynorphin/Kappa Opioid Receptor (KOR) activity has been known to mediate negative emotional states inducing, dysphoria, aversions, and depression. CRF also produces dysphoria, aversion and anxiety-like behavior via dynorphinergic interactions, and it has been hypothesized that the increased release of CRF may be a primary contributor in the development of anxiety disorders. Therefore, we propose to examine the role and interactions of CRF and dynorphin in the mediation of aversive behaviors and whether this in turn modulates nicotine withdrawal. This five-year project has three specific aims. In the first aim (during the K99 phase) we will determine whether dynorphin regulates aversion in the ventral NAc. The second aim (during the K99 phase) is to examine the mechanisms in which nicotine interacts with the dynorphin/kappa opioid system to regulate negative affective behaviors. Here we will determine whether stimulation of dynorphin containing neurons in the NAc mediates aversion and withdrawal behavior and whether this is KOR-dependent. In these aims we will quantify dynorphin release in the NAc following optogenetic stimulation. During the R00 independent phase (Aim 3) we will quantify dynorphin release in the NAc before and following chronic nicotine exposure. We will also optogenetically stimulate CeA- CRF containing neurons and measure dynorphin release in the NAc, to examine whether CRF regulates dynorphin release and behavior characteristic of withdrawal. Since, both CRF and dynorphin are involved in the stress response and preliminary data has shown that chronic stress can block KOR-induced drug seeking, we will also determine the role of CRF1-R/KOR interactions in reinstatement of nicotine seeking, following exposure to stress. Together this work has important therapeutic implications as it will enhance our understanding of dynorphin/CRF cell-types, neural circuits that modulate negative affective behaviors.

描述（由申请人提供）：本研究的总体目标是更好地了解强啡肽和 CRF 在与尼古丁戒断相关的负面情感行为中的作用。强啡肽和 CRF 系统均已被证明可以驱动压力和厌恶行为，但很少有研究确定这些系统如何相互调节以通过扩展的杏仁核驱动这些行为。已知强啡肽/Kappa 阿片受体 (KOR) 活性可介导诱发烦躁、厌恶和抑郁的负面情绪状态。 CRF 还通过强啡能相互作用产生烦躁、厌恶和焦虑样行为，并且推测 CRF 释放的增加可能是焦虑症发展的主要因素。因此，我们建议研究 CRF 和强啡肽在介导厌恶行为中的作用和相互作用，以及这是否反过来调节尼古丁戒断。这个为期五年的项目有三个具体目标。第一个目标（在 K99 阶段）我们将确定强啡肽是否调节腹侧 NAc 的厌恶。第二个目标（在 K99 阶段）是检查尼古丁与强啡肽/卡帕阿片系统相互作用以调节负面情感行为的机制。在这里，我们将确定刺激 NAc 中含有强啡肽的神经元是否会介导厌恶和退缩行为，以及这是否是 KOR 依赖性的。为了实现这些目标，我们将量化光遗传学刺激后 NAc 中强啡肽的释放。在 R00 独立阶段（目标 3），我们将量化慢性尼古丁暴露前后 NAc 中强啡肽的释放。我们还将通过光遗传学刺激含有 CeA-CRF 的神经元并测量 NAc 中的强啡肽释放，以检查 CRF 是否调节强啡肽释放和戒断行为特征。由于 CRF 和强啡肽都参与应激反应，并且初步数据表明慢性应激可以阻止 KOR 诱导的药物寻求，因此我们还将确定 CRF1-R/KOR 相互作用在接触尼古丁寻求恢复后的作用。压力。这项工作具有重要的治疗意义，因为它将增强我们对强啡肽/CRF 细胞类型、调节负面情感行为的神经回路的理解。

项目成果

Ventral tegmental area GABAergic inhibition of cholinergic interneurons in the ventral nucleus accumbens shell promotes reward reinforcement.

腹侧被盖区腹侧伏隔核壳中胆碱能中间神经元的 GABA 能抑制促进奖赏强化。

• 发表时间: 2021-10
• 影响因子: 25
• 作者: Al;Gowrishankar, Raajaram;Schmitz, Gavin P;Pedersen, Christian E;Marcus, David J;Shirley, Sofia E;Hobbs, Taylor E;Elerding, Abigail J;Renaud, Sophie J;Jing, Miao;Li, Yulong;Alvarez, Veronica A;Lemos, Julia C;Bruchas, Michael R
• 通讯作者: Bruchas, Michael R

Preparation and implementation of optofluidic neural probes for in vivo wireless pharmacology and optogenetics.

用于体内无线药理学和光遗传学的光流控神经探针的制备和实施。

• 发表时间: 2017-02
• 影响因子: 14.8
• 作者: McCall, Jordan G;Qazi, Raza;Shin, Gunchul;Li, Shuo;Ikram, Muhammad Hamza;Jang, Kyung;Liu, Yuhao;Al;Bruchas, Michael R;Jeong, Jae;Rogers, John A
• 通讯作者: Rogers, John A

Nicotine aversion is mediated by GABAergic interpeduncular nucleus inputs to laterodorsal tegmentum.

尼古丁厌恶是由 GABA 能脚间核输入外侧被盖介导的。

• 发表时间: 2018-07-13
• 影响因子: 16.6
• 作者: Wolfman, Shannon L;Gill, Daniel F;Bogdanic, Fili;Long, Katie;Al;McCall, Jordan G;Bruchas, Michael R;McGehee, Daniel S
• 通讯作者: McGehee, Daniel S